Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Lymphoma Leukemia Clinical Trial

Official title:
Phase I/II First-in-Human Trial With CAR19 Regulatory T Cells (CAR19-tTreg) in Adults With Relapsed/Refractory CD19+ B Acute Lymphocytic Leukemia

Status Not yet recruiting

Clinical Trial Summary

This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL). The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05114837
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact	Cancer Center Clinical Trials Office
Phone	612 624 2620
Email	ccinfo@umn.edu
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	May 2024
Completion date	August 2028

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03811457` - Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma	N/A
	Not yet recruiting	`NCT03975205` - To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames	Early Phase 1